Alexion Pharmaceuticals
 |
|
| Public | |
| Traded as |
|
| Industry | Pharmaceutical |
| Founded | 1992 |
| Founder | Leonard Bell, M.D. |
| Headquarters | New Haven, Connecticut, U.S. |
|
Key people
|
Leonard Bell (Chairman) Ludwig N. Hantson (CEO) |
| Products | Soliris |
| Revenue |
 US$2.6 bil (2015)
|
 US$536.67 mil (2015)
|
|
|
US$144.38 mil (2015)
|
|
| Total assets |
US$13.1 bil (2015)
|
| Total equity |
US$8.26 bil (2015)
|
|
Number of employees
|
2924(December 2015) |
| Website | www |
Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company is also involved in immune system research related to autoimmune diseases. It employs about 2,400 people worldwide. In February 2016, the company held the dedication ceremony for its new headquarters in New Haven, CT, not far from the company's starting point in the same city.
Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Leonard Bell. Bell would serve as the company's CEO until 2015. In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. Alexion moved back to New Haven following the completion of New Haven's Downtown Crossing project in December 2015 - Alexion's new headquarters are located at 100 College Street
Since 2006, Alexion has been a supporter of Healthcare Research and Quality studies at Duke University for aspirin and Clopidogrel (trade name Plavix).
Alexion received US Food and Drug Administration (FDA) approval for Soliris in 2007. It was initially approved to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder. In 2010, there was an outbreak of hemolytic-uremic syndrome caused by Enterohaemorrhagic Escherichia coli (EHEC) in Germany. Soliris was considered as a treatment option due to its effectiveness in treating Atypical hemolytic uremic syndrome, an illness similar to the one caused by the EHEC infection. As a result, Alexion's German subsidiary provided an unspecified number of Soliris doses at no charge to physicians who requested it.
...
Wikipedia